NeXT Personal
Comprehensive tumor profiling for precision oncology
Platform · OtherCompany source
Company profile
About Personalis
Personalis is a precision oncology company focused on transforming the active management of cancer through advanced genomic technologies. The company develops and commercializes comprehensive genomic sequencing and analysis solutions that enable cancer detection, monitoring, and personalized treatment strategies. Personalis serves the oncology research community, biopharmaceutical companies conducting clinical trials, and healthcare providers seeking to implement precision medicine approaches. Their technology platform combines whole genome, whole exome, and targeted sequencing capabilities with proprietary bioinformatics to deliver deep insights into tumor biology and immune response. The company's solutions support both tissue-based tumor profiling and liquid biopsy applications for minimal residual disease detection and treatment monitoring. By providing highly sensitive and comprehensive genomic analysis, Personalis aims to enable earlier cancer detection, more precise treatment selection, and better patient outcomes. Their platform is designed to support the full continuum of cancer care from initial diagnosis through treatment monitoring and surveillance for recurrence.
Company description Personalis official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Personalis?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Cancer
- Oncology
Who it serves
- Biopharmaceutical companies
- Healthcare providers
- Oncology researchers
- Pharma
Deployment & integration
Other deployment with recorded integration context.
Geographic context
MarketsNot currently listed
Company sourceOfficial website
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Circulating tumor DNA dynamics in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer assessed using an ultrasensitive tumor-informed assay.ESMO open · Aug 19, 2026
Ultrasensitive circulating tumor DNA detection improves prognostication in triple-negative breast cancer postneoadjuvant therapy.ESMO open · Jul 30, 2026
Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial.JAMA oncology · Jun 25, 2026
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · May 10, 2026
Predictors of Immune Checkpoint Blockade Response in dMMR Colorectal Cancer Using an Integrated Immune-Enhanced Multi-Omics Platform.Clinical cancer research : an official journal of the American Association for Cancer Research · Apr 17, 2026
Monitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patients.Scientific reports · Mar 23, 2026
Clinical validation
Clinical-trial records
NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal CancerNCT05197322 · Sponsor · ACTIVE NOT RECRUITING
Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)NCT06225505 · Sponsor · RECRUITING
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
No Company-reported outcomes are currently listed.
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Personalis
Recent articles published on Personalis's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.